Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys

Movement Disorders

Volumn 13, Issue 5, 1998, Pages 798-802

  Blanchet, Pierre J ^a   Konitsiotis, Spyridon ^a   Chase, Thomas N ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Dyskinesia; Levodopa; MPTP; Parkinson's disease

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; BENSERAZIDE; CARBIDOPA PLUS LEVODOPA; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DYSKINESIA; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AMANTADINE; ANIMALS; ANTIPARKINSON AGENTS; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; INJECTIONS, SUBCUTANEOUS; LEVODOPA; MACACA FASCICULARIS; NEUROLOGIC EXAMINATION; PARKINSON DISEASE, SECONDARY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0031689728     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870130507     Document Type: Article

References (19)

1. Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 1995;701:13-18.
2. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996;39:574-578.
3. Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 1991;206:297-300.
4. Blanchet P, Bedard PJ, Britton DR, Kebabian JW. Differential effect of selective D-l and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine-exposed monkeys. J Pharmacol Exp Ther 1993;267:275-279.
5. Verhagen Metman L, van den Munckhof P, Klaassen AAG, Blanchet P, Mouradian MM, Chase TN. Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease. Neurology 1997;49:711-713.
6. Blanchet PJ, Verhagen Metman L, Mouradian MM, Chase TN. Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov Disord 1996;11:580-581.
7. Rajput AH, Uitti RJ, Lang AE, Rajput AH, Kumar R, Galvez-Jimenez N. Amantadine ameliorates levodopa induced dyskinesia [Abstract]. Neurology 1997;48:A328.
8. Gomez-Mancilla B, Bédard PJ. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 1993;16:418-427.
9. Menon MK, Clark WG, Fleming RM. Blockade of the central effects of D-amphetamine sulfate by amantadine hydrochloride. Eur J Pharmacol 1973;21:311-317.
10. Andreassen OA, Aamo TO, Jørgensen HA. Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats. Br J Pharmacol 1996;119:751-757.
11. Kulisevsky J, Tolosa E. Amantadine in Parkinson's disease. In: Koller WC, Paulson G, eds. Therapy of Parkinson's Disease. New York, NY: Marcel Dekker, Inc, 1990:143-160.
12. Rojas P, Altagracia M, Kravzov J, Rios C. Amantadine increases striatal dopamine turnover in MPTP-treated mice. Drug Development Research l993;29:222-226.
13. Jackisch R, Link T, Neufang B, Koch R. Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties. Arch Int Pharmacodyn Ther 1992:320:21-42.
14. Gianutsos G, Chute S, Dunn JP. Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol 1985:110:357-361.
15. 2 responses in the 6-hydroxydopamine model of Parkinson's disease. Eur J Pharmacol 1990:182:611-612.
16. Oh JD, Del Dotto P, Chase TN. Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemiparkinsonian rat. Neurosci Lett 1997;228:5-8.
17. Schneider JS. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 1989:34:193-196.
18. Gagnon C, Bédard PJ, Di Paolo T. Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists. Eur J Pharmacol 1990;178:115-120.
19. 2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res 1993:602:290-303.